Ebglyss FDA approval intensifies competition in atopic dermatitis market: GlobalData
Eli Lilly’s Ebglyss enters the US market, poised to challenge established therapies like Dupixent and Adbry/Adtralza in the atopic…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
atopic dermatitis
Atopic Dermatitis: A hotspot for innovation and investment opportunities, says GlobalData
With the growth in AD, investment opportunities seem to be exciting, and pharmaceutical companies could invest in the R&D of…
Atopic dermatitis treatment sees promising future with new drug approvals: GlobalData
With the recent approvals of VTAMA in Japan and ZORYVE in the US, the atopic dermatitis landscape is evolving to better address…
Glenmark partners with Pfizer to launch Abrocitinib in India
When launched in India, it will be co-marketed under the brand names JABRYUS and CIBINQO by Glenmark and Pfizer respectively
Ichnos Sciences signs licensing pact with Astria Therapeutics for OX40 antagonist monoclonal…
Astria Therapeutics is granted global rights to develop and commercialise OX40 portfolio, comprised of Telazorlimab and its…
Dupixent (dupilumab) gets DCGI approval to treat moderate-to-severe atopic dermatitis
Dupilumab is being jointly developed by Sanofi and Regeneron under a global collaboration agreement
Sun Pharma starts Phase II trial of SCD-044 for moderate to severe plaque psoriasis
SCD-044 is also being evaluated in other autoimmune disorders and Phase 2 studies for other indications like atopic dermatitis,…
SPARC and Sun Pharma enter into license agreement for SCD-044
It is a potential treatment for atopic dermatitis, psoriasis and other auto-immune disorders